Exploring Antibody–Drug Conjugates in Early-Stage TNBC: Insights from a Clinical Trial

The role of antibody–drug conjugates (ADCs) in early-stage triple-negative breast cancer (TNBC) is an area of active investigation, with emerging clinical trial data shaping future treatment paradigms. The NeoSTAR trial evaluated a neoadjuvant, response-guided approach using sacituzumab govitecan in patients with early-stage TNBC, offering important insights into the feasibility and activity of ADCs in this setting. Results from NeoSTAR highlight the potential for ADCs to induce meaningful pathologic responses while providing an alternative strategy for patients who may not achieve optimal benefit from standard chemotherapy-based regimens. These findings also raise important questions around patient selection, sequencing with existing neoadjuvant therapies, and integration with immunotherapy. As evidence continues to evolve, studies like NeoSTAR help inform how ADCs may be incorporated earlier in the disease course to improve outcomes for patients with TNBC.